- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. (Pubmed Central) - Dec 16, 2020 Automated quantification of the fluid response may improve therapeutic management of neovascular AMD, avoid discrepancies between clinicians/investigators, and establish structure/function correlations. This analysis of combined morphologic and functional outcomes of anti-VEGF therapy, the largest conducted to date in nAMD, identified relatively low anti-VEGF injection frequencies, coupled with moderate anatomic and limited VA improvements, in United States clinical practice.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Trial completion, Enrollment change: Cytokeratin 8 Level in Age-related Macular Degeneration (clinicaltrials.gov) - Dec 9, 2020 P=N/A, N=58, Completed, Intravitreal injection of ranibizumab is a superior treatment modality for DME compared with SML regarding both anatomical and functional outcomes. Recruiting --> Completed | N=40 --> 58
- |||||||||| Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial completion date, Trial primary completion date: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion (clinicaltrials.gov) - Dec 3, 2020 P4, N=110, Recruiting, Different OCT patterns in DME may affect the therapeutic role of anti-VEGF agents and predict the structure outcome. Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Aug 2022 | Trial primary completion date: Mar 2020 --> Nov 2021
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Determinants in Initial Treatment Choice for Diabetic Macular Edema. (Pubmed Central) - Nov 28, 2020 Further studies with longer follow-up are warranted. Patient choices such as copays and where they live are important factors in determining the initial choice of treatment for DME.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Hyperreflective Walls in Foveal Cystoid Spaces as a Biomarker of Diabetic Macular Edema Refractory to Anti-VEGF Treatment. (Pubmed Central) - Nov 26, 2020 Foveal cystoid spaces with hyperreflective walls were often persistent, and the cumulative rates of DME remission among eyes with and without the hyperreflective walls were 7.7% (1 eye) and 48.8% (20 eyes) at 18 months (hazard ratio, 0.092; P = 0.025). We characterized hyperreflective walls in foveal cystoid spaces and designated them as a predictor of no DME remission under ranibizumab injections.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB. (Pubmed Central) - Nov 14, 2020 Ranibizumab was well-tolerated and demonstrated a good safety profile. The odds of endophthalmitis with aflibercept and ranibizumab combined were higher compared with the sterilely preloaded bevacizumab, arguing for a safety advantage of sterile preloading of anti-vascular endothelial growth factor injections.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy. (Pubmed Central) - Nov 12, 2020 Patients ⩾50 years with active neovascular age-related macular degeneration, best-corrected visual acuity between 20/32 and 20/320 with suboptimal response to ranibizumab or bevacizumab...Almost half of patients presented no fluid on optical coherence tomography at week 12, and there was a clinically significant improvement in best-corrected visual acuity. At week 40, one in five patients did not show intra or subretinal fluid, central macular thickness decreased and best-corrected visual acuity was stabilized compared to baseline.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal, HEOR: Vision-related quality of life in patients treated for myopic choroidal neovascularization: A post hoc analysis of the OLIMPIC study. (Pubmed Central) - Nov 12, 2020 To investigate vision-related quality of life in patients referred to the Italian Retina Services for intravitreal ranibizumab treatment for choroidal neovascularization due to pathologic myopia...Italian patients with myopic choroidal neovascularization and a low income presented with lower better-eye best-corrected visual acuity and lower vision-related quality of life compared with those with a higher income. Future research should investigate disease awareness and candidacy issues that may influence the quality of life of patients.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: VEGF: A KEY PLAYER NOT ONLY IN MACULAR DEGENERATION. A REVIEW. (Pubmed Central) - Nov 11, 2020 Some of the drugs have gradually found their use in other indications (central retinal vein occlusion or diabetic macular edema). The following text gives a brief look at the physiology of VEGF, but not only in the eye, but throughout the human body, particularly in the context of adverse effects resulting from systemic inhibition of its effects.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] 629: Diabetic Retinopathy Treatments: Clinically Relevant Results From the DRCR Network () - Nov 11, 2020 - Abstract #AAO2020AAO_1598; In addition, the attendee will learn clinically relevant secondary results from a study evaluating the comparative effectiveness of aflibercept, bevacizumab or ranibizumab for DME and the comparative effectiveness of panretinal photocoagulation with anti-VEGF treatment for proliferative diabetic retinopathy. Finally, the attendee will be able to apply the DRCR Network results to clinically relevant situations in daily practice.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] PO419: Gender Differences in Physician-Industry Interactions and Anti-VEGF Use Among U.S. Ophthalmologists () - Nov 11, 2020 - Abstract #AAO2020AAO_781; Results Of 3,957 physicians included, 57% received industry payments related to brand anti-VEGF (aflibercept and ranibizumab)...Number of industry payments was positively correlated with total anti-VEGF injection use (r = .38), total brand anti-VEGF injection use (r = .42) and percentage of brand anti-VEGF injection use (r = .32; all P < .001), regardless of gender. Conclusion Men received significantly more industry payments than women, and for both genders, number of industry payments correlated with greater use of brand anti-VEGF.
|